New drug cocktail aims to tackle Hard-to-Treat cancers

NCT ID NCT06499350

Recruiting now Disease control Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a combination of two drugs—FC084CSA and tislelizumab—in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and see if the combo can control tumor growth. Only 33 participants will be enrolled, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FC084CSA (AXL inhibitor) combined with tislelizumab (PD-1 inhibitor)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early, small trial (33 people) focused on safety and dosing. The combination may not shrink tumors or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMORS

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.